 |
24 Diseases |  |
14 Trials |
|
14 Trials |  |
566 News |  |
| «12345678» |
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Phase classification, Trial primary completion date: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ? 60 Years (clinicaltrials.gov) - Sep 30, 2016
P3b, N=150, Recruiting, Sponsor: Gilead Sciences
Phase classification: P3 --> P3b | Trial primary completion date: Jul 2017 --> Apr 2017
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (clinicaltrials.gov) - Aug 15, 2016
P3b, N=100, Recruiting, Sponsor: Gilead Sciences
Phase classification: P3 --> P3b | Trial primary completion date: Jul 2017 --> Apr 2017 Trial primary completion date: Apr 2017 --> Oct 2017
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P2 trial: Early ART to Limit Infection and Establishment of Reservoir (clinicaltrials.gov) - Aug 9, 2016
P2, N=150, Not yet recruiting, Sponsor: AIDS Clinical Trials Group
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Trial primary completion date: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Aug 2, 2016
P3b, N=240, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Apr 2017 --> Oct 2017 Trial primary completion date: May 2017 --> Aug 2017
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial initiation date, Trial primary completion date: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals (clinicaltrials.gov) - Jun 28, 2016
P=N/A, N=14, Recruiting, Sponsor: University of California, San Diego
Trial primary completion date: May 2017 --> Aug 2017 Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Oct 2015 --> Jan 2017
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults (clinicaltrials.gov) - Jun 27, 2016
P3, N=158, Completed, Sponsor: Gilead Sciences
Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Oct 2015 --> Jan 2017 Active, not recruiting --> Completed
- || Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Phase classification: Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (clinicaltrials.gov) - Jun 24, 2016
P3b, N=300, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Phase classification: P3 --> P3b
- ||||| New P4 trial, Adherence: Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy (clinicaltrials.gov) - Jun 16, 2016
P4, N=100, Not yet recruiting, Sponsor: mHealth UCSD
- || Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Phase classification: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Jun 9, 2016
P3b, N=240, Recruiting, Sponsor: Gilead Sciences
Phase classification: P3 --> P3b Phase classification: P3 --> P3b
- || Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Phase classification: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (clinicaltrials.gov) - Jun 9, 2016
P3b, N=100, Recruiting, Sponsor: Gilead Sciences
Phase classification: P3 --> P3b Phase classification: P3 --> P3b
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Phase classification: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis (clinicaltrials.gov) - Jun 5, 2016
P3b, N=50, Recruiting, Sponsor: Gilead Sciences
Phase classification: P3 --> P3b Phase classification: P3 --> P3b
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment change: Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults (clinicaltrials.gov) - May 24, 2016
P3, N=55, Active, not recruiting, Sponsor: Gilead Sciences
Phase classification: P3 --> P3b N=100 --> 55
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Enrollment open: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Apr 10, 2016
P3, N=240, Recruiting, Sponsor: Gilead Sciences
N=100 --> 55 Not yet recruiting --> Recruiting
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial initiation date: CTN289: HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (clinicaltrials.gov) - Mar 18, 2016
P3, N=25, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
Not yet recruiting --> Recruiting Initiation date: Jan 2016 --> Apr 2016
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
New P3 trial: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Mar 14, 2016
P3, N=240, Not yet recruiting, Sponsor: Gilead Sciences
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women (clinicaltrials.gov) - Feb 17, 2016
P3, N=400, Recruiting, Sponsor: Gilead Sciences
Initiation date: Jan 2016 --> Apr 2016 Not yet recruiting --> Recruiting
- ||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: CTN289: HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (clinicaltrials.gov) - Jan 21, 2016
P3, N=25, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women (clinicaltrials.gov) - Jan 15, 2016
P3, N=400, Not yet recruiting, Sponsor: Gilead Sciences
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial primary completion date: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (clinicaltrials.gov) - Jan 15, 2016
P3, N=100, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2017 --> Mar 2017
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial primary completion date: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis (clinicaltrials.gov) - Jan 15, 2016
P3, N=50, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2017 --> Mar 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Sep 2017
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ? 60 Years (clinicaltrials.gov) - Jan 7, 2016
P3, N=150, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov) - Dec 23, 2015
P2/3, N=73, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed, Enrollment change: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents (clinicaltrials.gov) - Dec 22, 2015
P2/3, N=60, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=50 --> 60
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (clinicaltrials.gov) - Dec 16, 2015
P3, N=300, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | N=50 --> 60 Not yet recruiting --> Recruiting
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ? 60 Years (clinicaltrials.gov) - Nov 30, 2015
P3, N=150, Not yet recruiting, Sponsor: Gilead Sciences
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (clinicaltrials.gov) - Nov 27, 2015
P3, N=100, Not yet recruiting, Sponsor: Gilead Sciences
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (clinicaltrials.gov) - Nov 17, 2015
P3, N=300, Not yet recruiting, Sponsor: Gilead Sciences
- ||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis (clinicaltrials.gov) - Nov 9, 2015
P3, N=50, Not yet recruiting, Sponsor: Gilead Sciences
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov) - Oct 22, 2015
P2/3, N=74, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> May 2016
- ||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial completion: Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination (clinicaltrials.gov) - Oct 22, 2015
P1, N=72, Completed, Sponsor: Janssen Sciences Ireland UC
Trial primary completion date: Nov 2016 --> May 2016 Active, not recruiting --> Completed
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial primary completion date: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov) - Aug 11, 2015
P2/3, N=74, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Nov 2016
- || Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment closed: Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination (clinicaltrials.gov) - Jul 29, 2015
P1, N=72, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Nov 2016 Recruiting --> Active, not recruiting
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment change: Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Jul 15, 2015
P2, N=279, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting N=150 --> 279
- Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
New P1 trial: Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination (clinicaltrials.gov) - Jun 18, 2015
P1, N=72, Recruiting, Sponsor: Janssen Sciences Ireland UC
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=14, Recruiting, Sponsor: University of California, San Diego
N=150 --> 279 Not yet recruiting --> Recruiting
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults (clinicaltrials.gov) - May 28, 2015
P3, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults (clinicaltrials.gov) - May 7, 2015
P3, N=170, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Aug 2015
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment change: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov) - Apr 17, 2015
P2/3, N=74, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Feb 2015 --> Aug 2015 N=50 --> 74
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment change: Efficacy and Safety of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Apr 14, 2015
P3, N=77, Active, not recruiting, Sponsor: Gilead Sciences
N=50 --> 74 N=125 --> 77
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents (clinicaltrials.gov) - Nov 27, 2014
P2/3, N=50, Recruiting, Sponsor: Gilead Sciences
N=125 --> 77 Not yet recruiting --> Recruiting
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults (clinicaltrials.gov) - Nov 24, 2014
P3, N=100, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> May 2016
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial initiation date: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals (clinicaltrials.gov) - Nov 11, 2014
P=N/A, N=14, Not yet recruiting, Sponsor: University of California, San Diego
Trial primary completion date: Oct 2014 --> May 2016 Initiation date: Oct 2014 --> Jan 2015
- |||| Tybost (cobicistat) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (clinicaltrials.gov) - Nov 5, 2014
P3, N=1500, Active, not recruiting, Sponsor: Gilead Sciences
Initiation date: Oct 2014 --> Jan 2015 Trial primary completion date: Oct 2014 --> Mar 2015
- ||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P2/3 trial: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents (clinicaltrials.gov) - Oct 28, 2014
P2/3, N=50, Not yet recruiting, Sponsor: Gilead Sciences
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Efficacy and Safety of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Sep 30, 2014
P3, N=125, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Oct 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Clinical: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=14, Not yet recruiting, Sponsor: University of California, San Diego
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed, Trial primary completion date: Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults (clinicaltrials.gov) - Sep 28, 2014
P3, N=170, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed, Trial primary completion date: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov) - Aug 29, 2014
P2/3, N=50, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Efficacy and Safety of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Aug 11, 2014
P3, N=125, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Sep 2015 --> Mar 2015
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment change: Efficacy and Safety of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Jun 19, 2014
P3, N=125, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2015 --> Mar 2015 N=100 --> 125